Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT03575403
PHASE1

Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)

Sponsor: Craig Rush

View on ClinicalTrials.gov

Summary

This study will evaluate the behavioral effects of alcohol during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.

Official title: A Novel Drug Combination for Alcohol-Use Disorders: A Human Laboratory Study

Key Details

Gender

All

Age Range

21 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

19

Start Date

2018-09-01

Completion Date

2023-03-15

Last Updated

2026-06-09

Healthy Volunteers

Yes

Interventions

DRUG

Alcohol

In each arm and during sessions, subjects will receive doses of alcohol designed to raise breath alcohol levels (BAL) to 0.03 g/dl.

DRUG

Placebos

Subjects will receive oral placebo capsules.

DRUG

Duloxetine (60 MG)

Subjects will receive 60-mg of oral duloxetine capsules.

DRUG

Methylphenidate

Subjects will receive methylphenidate capsules.

DRUG

Duloxetine (30 MG)

Subjects will receive 30-mg of oral duloxetine capsules.

Locations (1)

University of Kentucky

Lexington, Kentucky, United States